Should targeted therapies such as Brentuximab or Crizotinib be used in the upfront management of anaplastic large cell lymphoma in a pediatric or AYA patient?

Good question. Importantly, I am assuming that the question is for ALK+ patients who have systemic disease because ALK inhibitors have no role in ALK- disease and cutaneous only ALCL is really an entirely different entity.

In fact, the question is the primary aim of COG trial ANHL12P1 which uses eith...